Medical News Observer

Key Points:

• scDrugPrio uses single-cell RNA sequencing data to build a comprehensive network model. It predicts the most effective medication for each patient’s unique disease profile.
• Initial applications in mice and patients with inflammatory bowel disease have shown that drugs chosen through digital twin analysis can significantly improve treatment outcomes.
• The research team aims to offer scDrugPrio as an accessible tool that promotes advances in personalized treatment strategies.

scDrugPrio Computational Model To Create Digital Twin

Researchers from Karolinska Institutet have developed a method to create a “digital twin” of an individual patient’s autoimmune disease. This digital twin is created using a comprehensive computer model called scDrugPrio. Leveraging single-cell RNA sequencing (scRNA-seq) data, scDrugPrio constructs comprehensive network models of inflammatory diseases, incorporating cell type-specific expression changes, altered cellular interactions, and drug pharmacological properties to prioritize and rank thousands of potential medications. 

Autoimmune diseases, which can involve changes in the activity of thousands of genes affecting billions of cells across different organs, present a formidable challenge due to their complexity and the variability between patients. By utilizing digital twins for drug selection, the research promises a future where patients receive the right medication from the outset. Thus potentially reducing suffering and healthcare costs. 

Study

The study’s methodology, which included analyzing the gene activity in detailed cell populations from tissue samples, suggests a path forward for treating autoimmune diseases and early disease prediction and prevention. By computationally treating these digital twins with thousands of drugs, the researchers can identify the most effective medication for each patient.

In mice with inflamed joints, the medication selected through the digital twin’s computational treatment approach successfully cured the condition. Furthermore, this computational method has been applied to digital twins of patients with inflammatory bowel disease. It showed that the computationally chosen treatments align well with the patients’ actual responses to their current medications.

Future plans

Researchers plan for clinical trials to tailor medication for inflammatory bowel disease patients. They also intend to expand the technique to other conditions. 

The research team aims to make these revolutionary methods and data freely available, fostering further advancements in personalized medicine.

Implications

These findings are crucial for tackling the issue of ineffective medication approaches for complex diseases. scDrugPrio’s development and validation underscore its potential for personalized, network-based drug discovery and treatment. Researchers are making it accessible as an R package for broader applications in personalized medicine for IMIDs.

References

• Schäfer, Samuel, Martin Smelik, Oleg Sysoev, Yelin Zhao, Desiré Eklund, Sandra Lilja, Mika Gustafsson, et al. “scDrugPrio: A Framework for the Analysis of Single-Cell Transcriptomics to Address Multiple Problems in Precision Medicine in Immune-Mediated Inflammatory Diseases.” Genome Medicine 16, no. 1 (March 20, 2024): 42. https://doi.org/10.1186/s13073-024-01314-7.
• SDTC-CPMed/scDrugPrio.” R. 2022. Reprint, SDTC-CPMed, March 27, 2024. https://github.com/